Morgan Stanley Maintains Overweight on Rubius Therapeutics, Lowers Price Target to $15

Morgan Stanley maintains Rubius Therapeutics (NASDAQ:RUBY) with a Overweight and lowers the price target from $17 to $15.

Benzinga · 11/15/2019 13:38

Morgan Stanley maintains Rubius Therapeutics (NASDAQ:RUBY) with a Overweight and lowers the price target from $17 to $15.